Study on the Effectiveness and Safety of Riliprubart Compared to Intravenous Immunoglobulin in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Study on the Effectiveness and Safety of Riliprubart Compared to Intravenous Immunoglobulin in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
- Disease:Chronic inflammatory demyelinating polyradiculoneuropathy
- Substances:Riliprubart
Germany- Participants:18–64 years · 65+ years
- Substances:Riliprubart
- Sponsor:Sanofi-Aventis Recherche & Developpement










